Bull and Bear

Bull and Bear

Verdict: Watchlist — the structural bull case (USPI as an ASC platform inside a hospital chassis) is real, but the deterministic data has already turned against it for the next 12 months. FY26 EBITDA growth guides to +1.5% versus +14% in FY25, FY26 Adjusted FCF less NCI is guided below FY25 actual, and USPI same-facility case volume printed −2.1% in FY25 — the very metric the bull's platform multiple depends on. Management has also explicitly stated it "cannot yet quantify" the 2027 OBBBA Medicaid hit, leaving the back-half of the thesis window open-ended. The bull's $244 mean-reversion math and the 9%/year buyback are intact, so this is not a short — but waiting for either (a) two clean prints of USPI same-facility case volume turning positive, or (b) management putting a number on OBBBA, costs little versus stepping in front of a cycle that has visibly turned.

Bull Case

Bull's price target: $244/share (+33% from $183.27) on 12–18 months. Method: EV/EBITDA mean reversion — 7.5x (halfway from current 6.4x toward the 16-yr mean of 8.3x) on FY26E Adj. EBITDA of $4.2B, triangulated against a SOTP midpoint of ~$20B equity. Disconfirming signal: USPI same-facility revenue growth under 4% for two consecutive quarters, OR a Wells notice / DOJ subpoena referencing the Fuzzy Panda outlier-payment allegations.

Bear Case

Bear's downside target: $122/share (−33% from $183.27) on 12–18 months. Method: 5.5x EV/EBITDA on $3.8B post-policy EBITDA (FY25 $4.566B less ~$250M EPTC less ~$500M base-case OBBBA Medicaid drag) — stressed-hospital trough multiples and the FY17 crisis-era floor on Tenet's own 16-yr history, cross-checked against UHS at 7.2x P/E and CYH peer comps. Cover signal: A 10-K Item 3 disclosure clearing the Fuzzy Panda allegations cleanly plus management quantifying OBBBA at sub-$200M annual EBITDA and reaffirming a $4.5B+ FY27 EBITDA guide.

The Real Debate

Verdict

Verdict: Watchlist. The bear carries more weight today because the bear's evidence is deterministic and already in the printed numbers — FY26 EBITDA growth has collapsed to +1.5%, FY26 FCF less NCI is guided below FY25 actual, USPI same-facility case volume is already negative, and management itself refuses to size the 2027 OBBBA hit. The single most important tension is the second one: USPI's same-facility case volume of −2.1% directly undermines the bull's right to ASC-platform multiples, because a platform that loses units cannot be valued on take-out comps drawn from growing platforms. The bull could still be right — the buyback retires shares at 9%/year independent of any rerate, the SOTP gap is real, and management has earned credibility by beating every guide since FY24 — so this is a watchlist setup, not a short. The verdict flips to Lean Long if either (a) USPI same-facility case volume prints non-negative for two consecutive quarters in 2H FY26, or (b) management quantifies OBBBA at sub-$200M annual EBITDA and reaffirms a $4.5B+ FY27 EBITDA guide. Until one of those lands, the cost of waiting is small relative to stepping in front of a cycle whose downside management has not yet sized.